Guidance on the Use of Glycoprotein IIb/IIIa Inhibitors in the Treatment of Acute Coronary Syndromes (TA47)

Technology Appraisal Guidance No. 47

Source: National Institute for Health and Care Excellence

Note: This guidance has been partially updated by ‘Unstable angina and NSTEMI’ (NICE clinical guideline 94) (www.nice.org.uk/guidance/CG94) as shown below.

1. Guidance

1.1 This recommendation no longer stands.

1.2 This recommendation has been updated and replaced by recommendation 1.3.9 in NICE clinical guideline 94.

1.3 This recommendation has been updated and replaced by recommendation 1.3.9 in NICE clinical guideline 94.

1.4 This recommendation has been updated and replaced by recommendations 1.2.1 and 1.2.2 in NICE clinical guideline 94.

1.5 This recommendation no longer stands.

1.6 This recommendation has been updated and replaced by recommendation 1.3.10 in NICE clinical guideline 94.

1.7 It is recommended that a GP IIb/IIIa inhibitor is considered as an adjunct to PCI for all patients with diabetes undergoing elective PCI, and for those patients undergoing complex procedures (for example, multi-vessel PCI, insertion of multiple stents, vein graft PCI or PCI for bifurcation lesions); currrently only abciximab is licensed as an adjunct to PCI. In procedurally uncomplicated, elective PCI, where the risk of adverse sequelae is low, use of a GP IIb/IIIa inhibitor is not recommended unless unexpected immediate complications occur.

1.8 GP IIb/IIIa inhibitors are not currently licensed in the UK for use as an adjunct to thrombolytic therapy in ST-segment-elevation MI.


The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://www.nice.org.uk/guidance/ta47

Copies of the document can also be obtained by contacting 0845 003 7783 or emailing publications@nice.org.uk and quoting reference number N0132.

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Guidance on the Use of Glycoprotein IIb/IIIa Inhibitors in the Treatment of Acute Coronary Syndromes.
Issue Date: September 2002
Review Date: July 2005


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in